Displaying drugs 14351 - 14375 of 15485 in total
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and …
Activated natural killer cell therapy
Investigational
Adenovirus/PNP
Investigational
ETBX-041
Investigational
Carlecortemcel-L
Investigational
PBCAR269A
Investigational
PBCAR20A
Investigational
P-2045 Re-188
Investigational
KAb201
Investigational
hu3S193
Investigational
Pritumumab
Investigational
Tamrintamab pamozirine
Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3.
Investigational
JCAR014
Investigational
Letetresgene autoleucel
Investigational
M-032
Investigational
Zevorcabtagene autoleucel
Investigational
Galinpepimut-S
Investigational
ST101 peptide
ST101 is a cell-penetrating peptide that disrupts the protein-protein interactions driving ATF5-regulated gene transcription.
Investigational
ONCOS-102
Investigational
GVAX
GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.
Investigational
OriCar-017
Investigational
Pelareorep
Investigational
G305
G305 is a recombinant NY-ESO-1 protein plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with LV305.
Investigational
Displaying drugs 14351 - 14375 of 15485 in total